US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics Inc (AXSM) ニュース

AXSM

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AXSM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/05/07	06 : 20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/05/06	21 : 09	IH Market News	Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/05/06	20 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/05/06	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/05/01	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Recognizes May as Mental Health Awareness Month	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/04/15	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/04/10	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/04/01	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/25	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/25	19 : 30	GlobeNewswire Inc.	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/19	20 : 00	GlobeNewswire Inc.	Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/05	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/01	08 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/01	08 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/03/01	07 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/27	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/23	22 : 10	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/20	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/20	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/20	19 : 37	IH Market News	Market Cautiousness Ahead of Retail Giants’ Earnings; Oil Prices Dip	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/02/15	05 : 46	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/01/23	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/01/08	21 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/01/04	21 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AXSM	Axsome Therapeutics Inc
2024/01/04	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones	NASDAQ:AXSM	Axsome Therapeutics Inc
2023/12/11	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting	NASDAQ:AXSM	Axsome Therapeutics Inc
2023/12/08	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AXSM	Axsome Therapeutics Inc
2023/12/07	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today	NASDAQ:AXSM	Axsome Therapeutics Inc
2023/11/22	21 : 00	GlobeNewswire Inc.	Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7	NASDAQ:AXSM	Axsome Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:AXSM

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Euro

Invesco QQQ Trust Series 1

Gold vs US Dollar

BNP Paribas (QX)

Deutsche Telekom (QX)

Bank of America

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約